|CUSIP No. 03890D108
||Page 3 of 5 Pages
Item 1. Security and Issuer
This Amendment No. 1 (“Amendment No. 1”) amends the
Schedule 13D, dated October 12, 2018, filed by Raymond
Tabibiazar, M.D., relating to shares of common stock, par value
$0.0001 per share, of Aravive, Inc. (formerly known as Versartis,
Inc.), a Delaware corporation (the “Issuer”). The Issuer’s
principal executive office is located at River Oaks Tower, 3730
Kirby Drive, Suite 1200, Houston, Texas 77098.
Item 2. Identity and Background
(a) The name of the reporting person is Raymond Tabibiazar, M.D.
(the “Reporting Person”).
(b) The business address of the Reporting Person is 245 First
Street, 18th floor, Cambridge, Massachusetts 02142.
(c) The principal occupation of the Reporting Person is Managing
Director of 526 Ventures and Chairman and Chief Executive Officer
of a Boston based biotechnology company. The Reporting Person
ceased to serve as a director of the Issuer on December 31,
(d) During the last five years, the Reporting Person has not been
convicted in a criminal proceeding (excluding traffic violations or
(e) During the last five years, the Reporting Person was not a
party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result was not or is not subject to
a judgment, decree or final order enjoining future violations of,
or prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such
(f) The Reporting Person is a citizen of the United States.
Item 3. Source and Amount of Funds or Other
Item 3 is hereby amended and supplemented as follows:
On January 3, 2019, Dr. Tabibiazar was issued (a) an
option to purchase 7,500 shares of Common Stock that vest (i)
625 shares of Common Stock vested immediately upon grant and
(ii) the balance vest pro rata on a monthly basis over the
next 33 months commencing on February 12, 2019 and (b) an
option to purchase 4,688 shares of Common Stock that vest (i) 1,563
shares of Common Stock vested immediately upon grant and (ii) 625
vested on a monthly basis over the next five months commencing on
February 3, 2019 with full vesting, if not fully vested at
such time, on the date of the Issuer’s next annual meeting of
stockholders and are now fully vested as of the date hereof.
On September 12, 2019, Dr. Tabibiazar was issued an
option to purchase 7,500 shares of Common Stock all of which vest
pro rata on a monthly basis commencing on October 12, 2019
with full vesting, if not fully vested by October 12, 2020, on
the date of the Issuer’s 2020 annual meeting of stockholders. The
options are fully vested.
On September 14, 2020, Dr. Tabibiazar was issued an
option to purchase 16,029 shares of Common Stock all of which vest
pro rata on a monthly basis commencing on October 14, 2020
with full vesting, if not fully vested by October 14, 2021, on
the date of the Issuer’s 2021 annual meeting of stockholders.
From April 5, 2021 through April 12, 2021,
Dr. Tabibiazar exercised options to purchase an aggregate of
58,406 shares of Common Stock that were scheduled to expire on
April 26, 2021 and pursuant to a Rule10b5-1 plan that the Reporting
Person entered into in December 2020 sold the shares that he
received upon exercise of such options. The exercise price of the
options was $0.06 per share.
Item 4. Purpose of Transaction
The disclosure provided in Item 3 above is incorporated herein by
Item 5. Interest in Securities of the Issuer
(a) See rows (11) and (13) of the cover pages to this
Amendment No. 1 to Schedule 13D for the aggregate number and
percentages of the Common Stock beneficially owned by the Reporting
Person. The percentages used in this Amendment No. 1 to Schedule
13D are calculated as described in footnote 1 to the cover pages to
this Amendment No. 1 Schedule 13D.